Catriona Yale - Dec 9, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Dec 9, 2022
Transactions value $
-$216,137
Form type
4
Date filed
12/13/2022, 07:24 PM
Previous filing
Nov 14, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $0 +19.2K +26.63% $0.00 91.3K Dec 9, 2022 Direct F1
transaction AKRO Common Stock Sale -$199K -4.6K -5.04% $43.18 86.7K Dec 12, 2022 Direct F2, F3
transaction AKRO Common Stock Sale -$17.6K -402 -0.46% $43.77 86.3K Dec 12, 2022 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +86.4K $0.00 86.4K Dec 9, 2022 Common Stock 86.4K $42.95 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 30, 2021, previously adopted by the Reporting Person.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.68 to $43.67, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.69 to $43.91, inclusive.
F5 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.